Your Alan Health provider can help you decide
Many patients experience substantial weight loss over 6-12 months, with an average reduction of 10-20% of their starting weight, depending on lifestyle habits and individual response to treatment
B., Inneh, A., & Patel, U
For users considering switching between GLP-1 medications , current evidence does not support choosing one over another specifically to reduce blood clot risk
Lately, a GLP-1R agonist, liraglutide, has also been approved by the FDA for the treatment of adolescent obesity [14]
The GLP-1R interacts with structurally related peptide hormone ligands, such as glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), parathyroid hormone, etc